Who
Arturo Molina
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Protagonist Therapeutics; Director, Forma Therapeutics Holdings; Chief Medical Officer, Sutro Biopharma; Chief Medical Officer, Cougar Biotechnology.
In numbers
- Trades disclosed
- 99
- Buys
- 1
- Sells
- 14
- Bought
- $50K
- Sold
- $13.1M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 7 May 2007
- Last trade
- 26 Mar 2026
- Last filed
- 27 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $121K15,000 at $8.04 | filing |
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M15,000 at $104.79 | filing |
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $121K15,000 at $8.04 | filing |
| 26 Mar 2026filed 27 Mar 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M15,000 at $104.79 | filing |
| 27 Jan 2026filed 27 Jan 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 27 Jan 2026filed 27 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $40K5,000 at $8.04 | filing |
| 27 Jan 2026filed 27 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $410K5,000 at $82.00 | filing |
| 27 Jan 2026filed 27 Jan 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 27 Jan 2026filed 27 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $40K5,000 at $8.04 | filing |
| 27 Jan 2026filed 27 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $410K5,000 at $82.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $40K5,000 at $8.04 | filing |
| 26 Jan 2026filed 27 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $411K5,000 at $82.28 | filing |
| 26 Jan 2026filed 27 Jan 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $40K5,000 at $8.04 | filing |
| 26 Jan 2026filed 27 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $411K5,000 at $82.28 | filing |
| 23 Jan 2026filed 27 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M13,151 at $82.42 | filing |
| 23 Jan 2026filed 27 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M13,151 at $82.42 | filing |
News
Arturo Molina appointed managing director of Covestro in Spaineuropean-coatings.com · 7 Oct 2026Comparing Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX)PTGX · dailypolitical.com · 22 Oct 2026Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by Wall Street Zen to BuyPTGX · dailypolitical.com · 11 Oct 2026
1 headline in the last 90 days name Arturo Molina; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.